EPPK1 as a Prognostic Biomarker in Type I Endometrial Cancer and Its Correlation with Immune Infiltration
Lu Liu,Shuang Yuan,Shouheng Yao,Wenjiao Cao,Lihua Wang
DOI: https://doi.org/10.2147/ijgm.s449986
IF: 2.145
2024-04-30
International Journal of General Medicine
Abstract:Lu Liu, 1 Shuang Yuan, 1 Shouheng Yao, 1 Wenjiao Cao, 1, 2 Lihua Wang 1 1 The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200030, People's Republic of China; 2 Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, 200030, People's Republic of China Correspondence: Lihua Wang; Wenjiao Cao, The International Peace Maternity and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University, No. 910, Hengshan Road, Xuhui District, Shanghai, 200030, People's Republic of China, Tel +86-21-18017316018, Fax +86-21-64073896, Email ; Purpose: Approximately 20% of patients with type I endometrial cancer (EC) of the uterus experience recurrence and metastasis. However, existing data do not provide sufficient evidence for the utility of protein levels as prognostic biomarkers in type I EC. This study aims to determine whether epiplakin1 (EPPK1) and progesterone receptor (PR) play a role in the recurrence and metastasis of type I EC. Methods: Following the Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK) for assessing the quality of biomarker research results, a retrospective analysis was conducted on clinical information and tissue samples of type I EC patients. Protein expression data and clinical data for type I EC were downloaded from The Cancer Proteome Atlas (TCPA) database. We utilized the Kaplan-Meier (K-M) method and Cox proportional hazards regression analyses to evaluate whether epiplakin1 (EPPK1), progesterone receptor (PR) and certain clinical parameters can serve as independent prognostic factors. The Immune Cell Abundance Identifier (ImmuCellAI) and Cancer Immunome Atlas (TCIA) were employed to predict responses to immunotherapy. Immunohistochemistry was carried out to assess the expression of EPPK1 in type I EC. Results: Type I EC patients with high EPPK1 and low PR expression had higher International Federation of Gynecology and Obstetrics (FIGO) stage, recurrence, and metastasis rates. Furthermore, EPPK1 was identified as an independent prognostic factor, and low expression of EPPK1 was predominantly observed in the POLE ultramutated (POLEmut) group, indicating a favorable prognosis. Additionally, the high EPPK1 expression group had a lower Immune Prognostic Score (IPS), suggesting that the high-expression group may not benefit from immune checkpoint inhibitors. Conclusion: High expression of EPPK1 is an independent prognostic factor in type I EC patients with low PR expression. It can identify a subgroup of patients at high risk of recurrence. A more aggressive treatment approach is recommended for these patients. Keywords: type I endometrial cancer, progesterone receptor, epiplakin1, prognostic biomarker, immunotherapy Endometrial cancer (EC) is the common gynecological cancer affecting women worldwide. 1 In recent years, the incidence rate continues to rise, but its mortality rate has risen faster than it, 2 and it ranks second among gynecological tumors in China. 3–5 According to Bokhman's classification, EC is divided into type I and type II. 6,7 Among these, type I EC is known as endometrial endometrioid carcinoma and is the most prevalent type, accounting for approximately 80–90% of cases. Most of these cases exhibit high expression of estrogen and progesterone receptors (ERs and PRs), leading to a more favorable prognosis and a higher 5-year survival rate. 8,9 The majority of type I EC cases are low-risk and are primarily followed up in outpatient settings. 10 However, approximately 20% of type I EC cases are invasive and have a poorer clinical outcome. 11 With the development of the Cancer Genome Atlas (TCGA) molecular subtyping, EC is categorized into four subgroups: POLE ultramutated (POLEmut), p53 mutant (p53abn), mismatch repair-deficient (MMRd), and non-specific molecular profile (NSMP). 12 This classification system has improved the current risk stratification, but the NSMP cases are almost entirely low-grade type I EC. 13 Nonetheless, some of these patients still experience recurrence. Therefore, there is currently a lack of protein-level biomarkers in clinical practice to early predict an adverse prognosis in type I EC. High expression of PR is positively correlated with the prognosis of EC, including survival rates and survival time. 14 Research has assessed PR expression in 832 samples from EC patients, suggesting that the absence of PR expression may predict lymph node metastasis and shorter disease-specific survival. 15 Low expression of PR in EC is associated with advanced stages, higher grades, -Abstract Truncated-
medicine, general & internal